Pancreatic cancer, colorectal cancer.
Conditions
Interventions
18F-Fluciclatide PET scan
Sponsors
LUMC
Eligibility
Inclusion criteria
Inclusion criteria: Biopsy proven primary colorectal adenocarcinoma or suspected pancreatic ductal adenocarcinoma, as agreed on by multidisciplinary team; No prior chemo(radio)therapy in rectal cancer patients. Patient scheduled to undergo surgery; Patients treated in the LUMC. Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations
Exclusion criteria
Exclusion criteria: Contraindication for PET (pregnancy, breast-feeding and severe claustrophobia); Impaired renal function (creatinine clearance 3 ULN or total bilirubin >2x ULN); Known allergy to pABA (p-aminobenzoate sodium salt); Presence of any psychological, familial, sociological or geographical conditionpotentially hampering compliance with the study protocol and follow-up schedule; Inability to tolerate lying supine for the duration of a PET/CT examination (~30min).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess feasibility and sensitivity of imaging tumor angiogenesis in PDAC and colorectal adenocarcinoma, using 18F-Fluciclatide. When successful, the data of this study will allow for a larger trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| To define the most optimal PET acquisition time interval after i.v. administration of 18F-Fluciclatide PET/CT; To validate 18F-Fluciclatide as a clinical marker of angiogenesis by immunohistochemistry assessment of angiogenesis in PDAC and colorectal adenocarcinoma resection specimens. | — |
Contacts
Public ContactFloris Vuijk
Leiden University Medical Center
Outcome results
None listed